Gout Management Guidelines

Indications for Urate-Lowering Therapy

The American College of Rheumatology strongly recommends urate-lowering therapy for patients with subcutaneous tophi, radiographic lesions attributable to gout, or frequent gout attacks (>2/year), with a high level of evidence 1, 2
Patients with a history of more than one gout attack but with infrequent attacks (<2/year) may be considered for urate-lowering therapy, with a moderate level of evidence 1, 2
The European League Against Rheumatism recommends urate-lowering therapy for patients with moderate to severe chronic kidney disease (stage ≥3) and a first gout attack, with a moderate level of evidence 1, 2
Urate-lowering therapy may be considered for patients with a first gout attack and a serum urate level >9 mg/dl, with a moderate level of evidence 1, 2
Patients with a history of kidney stones and hyperuricosuria may benefit from urate-lowering therapy, with a moderate level of evidence 1, 2

The American College of Rheumatology recommends maintaining a serum urate level <6 mg/dl for all patients on urate-lowering therapy, with a high level of evidence 3, 4
For patients with severe gout (tophi, chronic arthropathy, frequent attacks), a target serum urate level <5 mg/dl is recommended until complete dissolution of urate crystals, with a moderate level of evidence 4
Long-term maintenance of a serum urate level <3 mg/dl is not recommended due to potential protective effects of urate against certain neurodegenerative diseases, with a moderate level of evidence 4

Asymptomatic hyperuricemia (serum urate >6.8 mg/dl without a history of gout attacks or subcutaneous tophi) is a conditional contraindication to initiating urate-lowering therapy, with a moderate level of evidence 1, 2
A first gout attack without specific comorbidities is a conditional contraindication to initiating urate-lowering therapy, with a moderate level of evidence 1, 2

Urate-lowering therapy reduces the risk of acute gout attacks, with a risk of approximately 5% at one year when serum urate is maintained <6 mg/dl, compared to 10-15% when ≥6 mg/dl, with a high level of evidence 6, 7
Urate-lowering therapy reduces the risk of developing nephropathy, with a risk of 4% vs 2% at one year and 9% vs 5% at three years for high vs low serum urate levels, with a moderate level of evidence 6, 7

The American College of Rheumatology recommends starting allopurinol at a low dose (100 mg/day) and increasing by 100 mg every 2-4 weeks until the target serum urate level is reached, with a moderate level of evidence 3
Prophylaxis with colchicine or low-dose NSAIDs is recommended during the initiation of urate-lowering therapy, with a moderate level of evidence 8

Urate-lowering therapy should be maintained for life once urate crystal dissolution is achieved, as approximately 40% of patients experience recurrence after stopping therapy, with a moderate level of evidence 4, 5
Regular monitoring of serum urate levels is essential to ensure that the therapeutic target is maintained, with a moderate level of evidence 4
The risk of allopurinol toxicity is increased in patients with renal insufficiency, requiring dose adjustment, with a moderate level of evidence 4
Initiating urate-lowering therapy can trigger acute gout attacks, emphasizing the importance of prophylaxis, with a moderate level of evidence 8, 4